Back to Feed
Fintech
Insmed Drug Misses Primary Goal, Program Axed
Benzinga·
Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to Brinsupri and Arikayce growth drivers.
Original Source
Benzinga — www.benzinga.com